2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|September 17, 2019
Acura and Catalent Team Up for LTX-03 Advancement
Author(s)Pharmaceutical Technology Editors
The companies have engaged in a manufacturing scale-up of LTX-03 tablets for clinical testing using LIMITx Technology.
Advertisement
Acura Pharmaceuticals announced it has initiated a manufacturing scale-up of LTX-03 (hydrocodone bitartrate and acetaminophen) tablets for clinical testing with Catalent Pharma Solutions.
According to a Sept. 9, 2019 press release, the tablets use LIMITx Technology, which is designed to obstruct the release of active drug ingredients when too many tablets are ingested by neutralizing stomach acid with buffer ingredients. The technology also delivers efficacious amounts of the drug when taken as a single tablet with a nominal buffer dose.
Four clinical studies of formulations using the technology have already been completed and showed proof-of-concept and have identified the key components of its formulation for advancement to formal clinical testing.
The formulation and manufacturing process optimization process for LTX-03 tablets is currently nearing completion.
Source:
Advertisement
Related to this article
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement